1 Efficacy and Safety of Chinese Herbal Injection Thoracic Perfusion

2 combined with Cisplatin chemotherapy for Lung Cancer Malignant

3 Pleural Effusion: A Systematic Review and Meta-Analysis

- 4 Zhong-Ning He^{1†}, Ming-Wan Su^{1†}, Jie-He^{1,2†}, Guang-Hui Zhu^{1†}, Yu-Wei Zhao^{1†}, Shu-Lin He, ^{1,2}
- 5 Yue Li^{1,2}, Bo-Lun Shi¹, Jia-Qi Hu^{1,2}, Shun-Tai Chen^{2*}, Bao-Jin Hua^{1*}
- ⁶ ¹Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 7 ²Beijing University of Chinese Medicine, Beijing, China

8 * Correspondence:

- 9 Shun-Tai Chen, Bao-Jin Hua share co-correspondence
- 10 qdyc31236@163.com, huabaojinxs@126.com
- 11 [†]Zhong-Ning He, Ming-Wan Su, Jie-He Guang-hui Zhu and Yu-Wei Zhao share co-first author.

12 **Purpose** To evaluate the efficacy and safety of Chinese herbal injection thoracic perfusion combined

13 with cisplatin chemotherapy for lung cancer patients with MPE.

14 Method Eight databases were searched for articles published from inception to August 20, 2022 for

15 randomized-controlled trials (RCTs) that are relevant. The included studies were reviewed by two

- 16 investigators, with relevant data extracted independently. Primary outcome was identified as
- 17 objective response rate (ORR), while secondary outcomes were identified as quality of life (QOL)
- 18 and adverse reactions. Quality of the included trials was assessed through risk of bias assessment of
- 19 the Cochrane risk-of-bias tool. The Revman5.3 and Stata17.0 software were used to calculate risk
- 20 ratio (RR) at 95% confidence intervals (CI) for binary outcomes.

21	Results 29 RCTs involvin	ng 1887 patie	ents were include	d in this study.	Compare	d with p	patients treated

- 22 with cisplatin thoracic perfusion alone, those with Chinese herbal injection and cisplatin thoracic
- 23 perfusion had better therapeutic effects (RR=1.44, 95% CI: 1.35~1.53, P = 0.000), higher KPS score
- 24 (RR = 1.47, 95%CI: $1.34\sim1.61, P = 0.0000$), lower digestive tract reaction(RR = 0.56, 95%CI:
- 25 $0.48 \sim 0.67$, P = 0.000), bone marrow suppression (RR = 0.50, 95% CI: 0.43 \sim 0.59, P = 0.000) and
- 26 chest pain reactions (RR = 0.65, 95%CI: $0.47 \sim 0.89$, P = 0.007).
- 27 Conclusion The systematic review indicated that Chinese herbal injection thoracic perfusion
- 28 combined with cisplatin chemotherapy may improve therapeutic effect, quality of life, and reduce
- adverse reactions. More large-scale and higher quality RCTs are warranted to support our findings.
- 30 Systematic Review Registration: PROSPERO, identifier CRD42022347345.
- 31 Keywords: Chinese Herbal, lung cancer, malignant pleural effusion, cisplatin , thoracic perfusion,
 32 systematic review, meta-analysis

33 1 Introduction

34 Lung cancer is one of the most common malignant tumors in the world, with high morbidity and 35 mortality^[1], Malignant Pleural Effusion (MPE) is a common complication in lung cancer patients. 36 and the median survival time is only 5.5 months^[2]. The occurrence of MPE is associated with poor 37 quality of life (QOL) and shorter survival time in lung cancer patients^[3]. Thus, effective treatment for 38 MPE appears very important. The main purpose is to control the effusion from growth, relieve 39 dyspnea, improve the quality of survival, to extend the survival. Currently, management options for 40 MPE includes chest tube drainage and systematic chemotherapy to achieve symptomatic relief and 41 controlling the primary malignancies. Thoracic perfusion of chemotherapeutic is an effective method 42 for the treatment of MPE, and thoracic perfusion of cisplatin has good pharmacodynamics^[4, 5], high 43 economic practicability^[6]. However, the side effects of cisplatin, such as gastrointestinal reactions

44 and hepatorenal toxicity, cannot be ignored, and will affect the quality of life of patients to a certain extent^[7]. Therefore, current management approach remain palliative. Thus, we seek to find an 45 46 effective combined treatment for MPE. In recent years, related studies have shown that anti-tumor 47 Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy in the treatment of 48 MPE have a positive effect in improving efficiency, improve the quality of life, reduce adverse 49 reactions^[8-10]. Although the clinical studies on Chinese herbal injection in the treatment of lung 50 cancer MPE are increasing, the long-term efficacy has not been measured. Lack of high quality, neat 51 standard clinical research, In order to obtain higher evidence data, this study using evidence-based 52 medicine method, comprehensive collection published in Chinese and English literature at present, 53 the systematic evaluation of Chinese herbal injection thoracic perfusion combined with cisplatin 54 chemotherapy of lung cancer MPE, curative effect in order to provide a basis for evidence based 55 medicine in the future clinical treatment.

56 2 METHODS

57 This study was conducted following the Preferred Reporting Items for Systematic Reviews and
58 Meta-Analyses (PRISMA) guidelines^[11]. The protocol has been registered in PROSPERO
59 (registration number: CRD42022347345).

60 **3** Search strategy

An independent review of citations was searched for articles published from inception to August 20,
2022, relevant publications evaluating the efficacy and safety of Chinese herbal injection for Lung
cancer with MPE were searched in the Chinese National Knowledge Infrastructure (CNKI), Wanfang
Database, the VIP Information Database, Chinese Biomedical Literature database (CBM), PubMed,
EMBASE, and the Cochrane Library. The following Key words were used: "Lung Neoplasms OR
Lung Cancer" AND "Pleural Effusion, Malignant OR Malignant Pleural Effusion" AND "Cisplatin"

72	4 Study selection and data extraction
71	Supplementary 1). The languages were restricted to Chinese and English.
70	retrievals were implemented using MeSH and free words (the detailed search strategy is available in
69	injection OR Shenqifuzheng injection OR Kang-Ai injection OR Kushenhuangqi injection". All
68	emulsion OR Yuxingcao injection OR Aidi injection OR Xiao-ai-ping injection OR Huachansu
67	AND "Elemene injection OR Kushen injection OR Kanglaite injection OR Brucea Javanica oil

Figible studies were randomized controlled trials of lung cancer adults (≥ 18) with MPE

74 involvingChinese herbal injection thoracic perfusion combined with cisplatin chemotherapy

comparing to cisplatin thoracic perfusion alone. We defined intervened injections as Elemene

76 injection, Kushen injection, Kanglaite injection, Brucea Javanica oil emulsion, Yuxingcao injection,

77 Aidi injection, Xiao-ai-ping injection, Huachansu injection, Shenqifuzheng injection, Kang-Ai

78 injection, Kushenhuangqi injection etc. Studies were excluded if patients were treated with other

79 chemotherapy.

Two reviewers Ming-Wan Su and Jie-He independently selected studies based on the inclusion and exclusion criteria described above. Two reviewers independently extracted details for each trial: first author name and year of publication, patient characteristics; Intervention: Chinese herbal injection, Cisplatin ingredients, dose, treatment time; primary and secondary outcome measures. Missing information can be obtained by contacting the author.

85 5 Data synthesis and analysis

86 The primary outcome measure is objective remission rate (ORR) of MPE which was defined as CR +

87 PR^[12]. Quality of life (QOL) evaluated with Karnofsky score. Adverse events (digestive tract

88 reactions, bone marrow suppression, chest pain) are second outcome measures. The data were

89 processed and analyzed by Stata 17.0 (Stata Corp, College Station, SE). Random-effects models were

90	performed to calculate pooled effects. Fixed-effect models were performed if statistical heterogeneity
91	was absent (heterogeneity test, $P \ge 0.10$), dichotomous data were presented as pooled Risk Ratio
92	(RR) with 95% confidence intervals (95% CIs), Assessment of heterogeneity was performed using
93	Cochran's Q test and Higgins's I^2 ; $I^2 > 50\%$ and a P value < 0.10 suggested significant
94	heterogeneity ^[13] . Sensitivity analysis was performed by sequentially omitting each study to examine
95	the robustness of the results. Potential publication bias was evaluated using Begg's funnel plot and
96	Egger's test ^[14] .

97 6 Risk of Bias Assessment

98 Two reviewers Zhong-Ning He and Guang-Hui Zhu independently assessed the quality of the

99 selected trials according to the RCT trials tool of the Cochrane Collaboration. Items were divided

100 into three categories: low risk bias, unclear bias and high-risk bias. The following features are

101 random sequence generation (selection bias), concealment of assignment (selection bias), blinding of

102 participants, personnel (performance bias), outcome data were incomplete (attrition bias), selective

103 reporting (reporting bias), and other bias. These assessments are plotted and evaluated using Review

104 Manager 5.3.

105 **7 Result**

106 7.1. Search Result

107 Initially 281 literatures from 7 electronic databases were identified. After the removal of 98

108 duplications and 55 irrelevants after screening through the title and abstract, 43 articles were consider

109 potentially appropriate for inclusion. Among which, 14 articles were excluded for the following

- 110 reasons: not lung cancer patient (n=2), not thoracic perfusion (n=4), Chinese herbal injection
- 111 intervention alone (n=6), Chinese herbal injection with other chemotherapy (n=2). Eventually, 29

- single-centered RCTs met all inclusion criteria,^[8-10, 15-40] as shown in the flow diagram (Locate Figure
 1)
- 114 **Figure 1** Flow diagram

115 7.2. Characteristics of the Included Studies

116 All 29 studies yielded a total of 1,887 patients. The baseline characteristics of each trial are presented 117 in Table 1. The control group was treated with cisplatin thoracic perfusion, on the basis of the control 118 group, the experimental group was infused with chinese herbal injection. 29 trials reported the ORR 119 following WHO guidelines, KPS was reported in 16 studies, and adverse events were reported in 24 120 studies, Among the 29 citations, intervention of experimental group was Aidi injection in 12 studies^[10, 18, 21, 24, 26, 30-32, 35-38]. Kushen injection in 10 studies^[8, 16, 17, 20, 22, 25, 27, 33, 34, 40], Brucea 121 122 Javanica oil emulsion in 3 studies^[9, 29, 39], and other injections were not included because less than 3 123 studies. A total of 16 studies reported OOL improvement (the number of patients KPS score 10 124 points higher or stable after treatment)^[8, 9, 15, 16, 21, 22, 24-27, 29, 33, 34, 36, 37, 39]. 24 studys that included 1,527 patients reported adverse reactions^[8, 9, 16-27, 29, 31-39]. Bone marrow suppression was recorded in 125 23 studies^[8, 9, 16-21, 23-27, 29-32, 34-39, 41]. 19 studys that included 1.353 patients reported chest pain^[9, 15, 16, 10]. 126 18-24, 26, 29, 31-33, 35, 37-39] 127

128 **Table1** Characteristics of the Included Studies

First	V			E		Interv	
First	K			E Chinese Herbal	cisplatin	entio	Outco
author,	Р	Years	M/F	/			
year	S			Injection C	(DDP)	n	mes
2						time	

				3 Brucea Javanica			
Wang, HM.20 07	> 5 0	26~81	45/2 5	 5 oil / emulsion,80~100 3 ml,5~7d/c,4cycle 	20~30mg/m ² , 5~7d/c,4cycle s	30da y	O1,2, 3,4,5
Hu,JC. 2008	> 5 0	65±15 /62±1 7	43/2 5	 5 s 3 6 Kushenhuangqi / injection,60ml,7 3 d/c,4cycles 5 	40mg/m²,7d/c ,4cycles	30da y	01,3, 4,5
Yao,Y W.200 8	≧ 6 0	38 ~ 85	33/1 3	2 3 Aidi / injection,100ml/ 2 d,7d/c,4cycles 3	30mg/d,7d/c, 4cycles	28da y	O1,2, 3,4,5
Li,YP. 2009	-	35~70	49/1 1	 3 0 Kushen / injection,20ml,7 3 d/c,4cycles 0 	40mg,7d/c,4c ycles	28da ys	O1,3, 4,5

				2 Brucea Javanica			
Zhang, SF.200 9	> 5 0	65~80	35/1 5	 7 oil / emulsion,50~100 2 ml,5~7d/c,4cycle 3 s 	20~30mg/m ² , 5~7d/c,4cycle s	30da ys	O1,2, 3,4,5
Meng,S L.2009	> 5 0	58~79	28/1 4	 2 Aidi / injection,50~80 2 ml,7d/c,4cycles 0 	20~30mg/m ² , 7d/c,4cycles	30da ys	O1,2, 3,4,5
He,L.2 010	-	39~75	25/1 9	 Kushen injection,40ml,7 d/c,3cycles 0 	40mg/m ² ,7d/c ,3cycles	21da ys	O1,2, 4
Wang, XH.20 10	-	20~69	47/1 3	 3 0 Aidi / injection,50ml,7 3 d/c,4cycles 0 	40mg,7d/c,4c ycles	28da ys	O1,4


Han,Z Q.2012	> 5 0	41~91	35/2 1	 2 8 Kushen / injection,20mg,7 2 d/c,2~4cycles 8 	20~40mg,7d/ c,2~4cycles	28da ys	O1,2, 3,4,5
Sun,SL .2012	> 5 0	43~74	27/1 3	2 1 Aidi / injection,50~80 1 ml,7d/c,4cycles 9	20~30mg/m ² , 7d/c,4cycles	28da ys	O1,2, 3,4,5
Liu,CX .2013	> 4 0	41~82	57/5 5	 5 6 Aidi / injection,100ml, 5 7d/c,4cycles 6 	30mg,7d/c,4c ycles	28da ys	O1,2, 3,4,5
Wang, XC.201 4	-	29~83	46/1 8	 3 2 Aidi / injection,40ml,7 3 d/c,4cycles 2 	60mg,7d/c,4c ycles	28da ys	O1,3, 4,5

Liu,D.2 015	> 6 0	60.2± 8.2	48/4 0	 4 6 Kushen / injection,20ml,7 4 d/c,3cycles 2 	40 ~ 60mg,7d/c,3c ycles	30da y	O1,2, 3,5
Yang,D F.2015	> 4 5	41~76	33/1 7	 Aidi injection,75ml/d, 7d/c,5cycles 	25mg/d,7d/c, 5cycles	35da ys	O1,2, 3,4
Wang, HX.20 16	-	64.5± 8.7	44/2 6	 3 5 Kushenhuangqi / injection,60ml,5 3 ~7d/c,4cycles 5 	40mg/m2,5~7 d/c,4cycles	28da ys	O1
Liu,L.2 017	≧ 5 0	32~76	-	 3 0 Kushen / injection,20ml,7 3 d/c,4cycles 0 	40mg,7d/c,4c ycles	28da ys	O1,2, 3,4

Liu,SY .2017	> 6 0	33~78	35/2 9	 3 2 Huachansu / injection,20ml,7 3 d/c,2cycles 2 	40mg,7d/c,2c ycles	30da ys	01,3, 4,5
Shen,S L.2017	≧ 6 0	48~70	52/2 8	4 Brucea Javanica 0 oil / emulsion,50ml,7 4 d/c,4cycles 0	50mg/m²/d,7 d/c,4cycles	28da ys	O1,2, 3,4,5
Shi,WJ .2017	≧ 5 0	34 ~ 78	39/2 1	 3 0 Kushen / injection,20ml,7 3 d/c,4cycles 0 	40mg,7d/c,4c ycles	28da ys	O1,2, 3,4
Hou,TJ ,2017	> 4 5	18~80	52/3 8	 Aidi injection,100ml, 7d/c,4cycles 	30mg,7d/c,4c ycles	28da ys	O1,3, 4,5

Shi,WL .2017	30 ~ 80	20/1 0	 Aidi injection,40ml,7 d/c,4cycles 	60mg,7d/c,4c ycles	28da ys	01
Wang, - Y.2017	44 ~ 72	45/1 9	 3 Aidi / injection,50~80 3 ml,7d/c,4cycles 2 	20~30mg/m ² , 7d/c,4cycles	28da ys	0,3,4 ,5
Chen,F - .2018	35 ~ 67	76/7 4	 7 5 Elemene / injection30mg,1d 7 /c,14cycles 5 	50mg,1d/c,14 cycles	14da y	01,2, 5
Tang,X Q.2018	33 ~ 77	-	 3 0 Kushen / injection,60ml,3 3 d/c,6cycles 0 	40mg,3d/c,6c ycles	21da ys	O1,2, 3,4

Zhu,X. 2018	-	36~75	27/2 3	 Kushen injection,20ml,7 d/c,3cycles 5 	60mg,7d/c,3c ycles	28da ys	O1
Wang, Y.2019	-	58~75	49/4 1	 Kushen injection,20ml,7 d/c,3cycles 	40 ~ 60mg,7d/c,3c ycles	21da ys	O1,2, 3,5
Wu,CY .2019	_	39 ~ 68	30/2 0	2 Kushen 5 injection,40~60 / ml,3~7d/c,4cycle s 5	40~60mg,7~1 4d/c,4cycles	30da ys	01,2, 3,4
Wu,M B.2020	-	50 ~ 78	25/1 1	 Aidi injection,50ml/d, 7d/c,12 ~ 18cycles 	25mg/d,7d/c, 12 ~ 18cycles	126d ay	01,3, 4,5



129 Note: M/F, male/female; KPS, Karnofsky score; E/C, experimental group/control group; O,

130 outcomes; O1, objective response rate (ORR); O2, Quality of Life (QOL); O3, Digestive tract

131 reaction; O4, Bone marrow suppression; O5, Chest pain

132 **7.3. Study quality and Risk of bias**

Among all studies included, 24 used random assignment^[8-10, 15-17, 19-29, 31, 32, 34-36, 38, 39], and seven of

them reported the way assignments were hidden^[15, 19, 22, 25, 31, 32, 35]. In terms of blind implementation,

135 none of the studies mentioned it. Two of the included studies may have had incomplete data records,

136 which have no effect on the results of the study ^[20, 40], for reasons not explained in the report. In

137 terms of selective reporting of outcomes, all studies reported treatment from two or more aspects,

138 with a low risk of reporting bias. In terms of other biases, 2 treatment methods of the experimental

139 groups were not exclusively described in 2 studies, which may have other biases^[15, 38]. Figure 2

140 shows more details. (LocateFigure2)

141 **Figure 2** Risk of bias summary and diagram. (A) Risk of bias summary. (B) Risk of bias diagram.

142 7.4. Primary outcomes

143 7.4.1 Objective Remission Rate (ORR)

144 Comparing to cisplatin thoracic perfusion, the ORR favored Chinese herbal injection group

145 (RR=1.44, 95% CI: 1.35~1.53, P = 0.000; $I^2 = 38.4\%$, P = 0.020). (LocateFigure 3)

- 146 **Figure 3** forest plot of ORR
- 147 **7.5. Secondary outcomes**
- 148 7.5.1 Quality of Life (QOL)
- 149 Compared with cisplatin thoracic perfusion alone, Chinese herbal injection thoracic perfusion
- 150 combined with cisplatin chemotherapy could significantly improve the KPS scores (RR = 1.47,
- 151 95%CI: 1.34~1.61, P = 0.0000), with low heterogeneity($I^2 = 0\%$, P=0.943), and there was a
- 152 statistical difference between the two groups. (LocateFigure 4)
- 153 **Figure 4** Meta-analysis of QOL

154 **7.5.2 Digestive tract reaction**

- 155 Comparing to cisplatin thoracic perfusion, Chinese herbal injection thoracic perfusion combined with
- 156 cisplatin chemotherapy significantly reduced the incidence of digestive tract reactions (RR = 0.56,
- 157 95%CI: 0.48~0.67, P = 0.000) with low heterogeneity ($I^2 = 27.5\%$, P = 0.106). (LocateFigure 5)
- 158 **Figure 5** | Meta-analysis of digestive tract reaction

159 **7.5.3 Bone marrow suppression**

- 160 The incidence of bone marrow depressions in experimental group was significantly ower than that in
- 161 control group (RR = 0.50, 95% CI: 0.43~0.59, P =0.000) with low heterogeneity (I^2 = 8.9%, P =
- 162 0.340). (LocateFigure 6)
- 163 **Figure 6** Meta-analysis of bone marrow suppression

164 **7.5.4** Chest pain


- 165 The experimental group significantly reduced the incidence of chest pain reactions (RR = 0.65,
- 166 95%CI: 0.47~0. 89, P = 0.007), with low heterogeneity ($I^2 = 0\%$, P = 0.631). (LocateFigure 7)

167 **Figure 7** Meta-analysis of Chest pain

168 **7.6 Subgroup analysis of QOL and Adverse reactions**

- 169 Among the 5 secondary outcome measures, subgroup analysis was performed according to the
- 170 difference of Chinese herbal injections. The results of subgroup analysis are shown in Table 2.
- 171 Compared with cisplatin thoracic perfusion alone, Aidi injection, Kushen injection, Brucea Javanica
- 172 oil emulsion combined with cisplatin thoracic perfusion in the treatment of MPE has a better
- 173 therapeutic effect in QOL, digestive tract reaction, and bone marrow suppression outcome, and the
- 174 differences are statistically significant, the results of subgroup analysis were consistent with the trend
- 175 of the overall combined results. But there was no statistically significant difference in the outcome
- 176 index of chest pain, which was different from the overall combined trend. (Table2)
- 177 **Table 2** results of subgroup analysis

Outcome	Pooled	Z	Р	Heterogeneity	
	RR(95%CI)				
				<i>I</i> ² (%)	P_{h}
	1 52(1 27 1 (0)	0.05	0.000	00/	0.000
Quality of	1.52(1.37,1.69)	8.05	0.000	0%	0.998
Life (QOL)					
Digestive	0.53(0.43,0.64)	6.37	0.000	27.9%	0.111
tract					
reaction					



178 **7.7 Moderator effects**

179 To investigate the sources of potential heterogeneity, we conducted subgroup analysis with 180 moderator variables include injection categories. According to the results of subgroup analysis in 181 Figure 8, it can be concluded that Aidi injection combined with cisplatin thoracic perfusion 182 (RR=1.37, 95%CI: 1.25~1.50, P = 0.000, $I^2 = 58.3\%$, P = 0.006), Kushen injection combined with 183 cisplatin thoracic perfusion (RR = 1.48, 95%CI: 1.32~1.66, P = 0.000, $I^2 = 0\%$, P=0.813). Brucea 184 Javanica oil emulsion combined with cisplatin thoracic perfusion was infused into the chest (RR = 185 1.68, 95%CI: 1.34~2.09, P = 0.000, $I^2 = 0\%$, P=0.964). Compared with cisplatin thoracic perfusion alone. all of them have more effective rate in the treatment of MPE, and the difference is statistically 186 187 significant. Therefore, the results of the subgroup analysis on ORR, the primary outcome measure, 188 were trend consistent with the overall pooled results (RR = 1.45, 95%CI: 1.35~1.55, P = 0.000, $I^2 =$ 189 45.2%, *P*=0.008). (LocateFigure8)

190 **Figure 8** Subgroup analysis of ORR

191 **7.8 Sensitivity analysis**

192	In this study, sensitivity analysis was conducted leave-one-out method, revealing that Hou TJ ^[18] had
193	a rather great impact on heterogeneity. After the elimination, I^2 decreased from 38.4% to 0%, but had
194	little effect on the final results (RR=1.44, 95% CI: 1.35~1.53, P = 0.000 vs RR:1.47, 95%CI:
195	1.37~1.56, P = 0.0000). There was a certain heterogeneity in subgroup analysis of ORR ($I^2 = 45.2\%$).
196	After deleting the study of Hou TJ ^[18] , I^2 decreased from 45.2% to 0%, but had little effect on the
197	final results (RR = 1.42, 95%CI: 1.30~1.55, $P = 0.000$ vs RR:1.40, 95%CI: 1.31~1.50, $P = 0.0000$).
198	(Figure 9A-B). Compared with other research, Hou TJ had a relatively high response rate, so as to
199	tilting the heterogeneity much heavier. For second outcome: Quality of life (QOL), digestive tract
200	reaction, bone marrow suppression and chest pain, outcome indicators found that the heterogeneity
201	among studies was small ($I^2 < 30\%$), and the inclusion of one study by one had little impact on the
202	results, so these results were stable (LocateFigure 9).

203 **Figure 9** (A) sensitivity analysis of ORR; (B) sensitivity analysis of Subgroup analysis of ORR; (C) 204 sensitivity analysis of OOL; (D) sensitivity analysis of digestive tract reaction; (E) sensitivity 205 analysis of bone marrow suppression; (F) sensitivity analysis of chest pain

206 7.9 Publication bias

207 Funnel plots were drawn according to the primary outcome measure ORR, we noticed that the 208 included study was distributed asymmetrically on both sides of the funnel chart (Figures 10A–C), 209 indicating that there was significant publication bias in the meta-analysis. The Begg (p=0.003) and 210 Egger (p=0.000) test was used to test the publication bias of 29 studies included in this meta-analysis, 211 and the results showed that this study had obvious publication bias (P < 0.05). The 29 articles included 212 in this study were analyzed by the trim-fill method, and the results showed that after the inclusion of 213 14 virtual studies, Meta-analysis was conducted again, using the fixed effect model, and the 214 combined results of effect indicators RR=1.229, 95%CI :1.171~1.289, although some small sample

studies were added to correct the publication bias, which did not have a significant impact on the

216 results. (LocateFigure10)

Figure 10 | (A) Funnel plot of ORR; (B) Egger test of ORR; (C) Begg test of ORR; (D) trim-fill

218 method of ORR

219 8 Discussion

220 The aim of this meta-analysis is to evaluate the efficacy and safety of Chinese herbal injection

thoracic perfusion combined with cisplatin chemotherapy in the treatment of lung cancer MPE.

222 Compared with the published meta-analysis^[42], our study is the first to control the administration

223 mode of traditional Chinese herbal injection as thoracic perfusion, using thoracic perfusion of

224 cisplatin as the control group, which ensures the consistency of intervention measures and can reduce

225 clinical heterogeneity to a certain extent. Our results demonstrated that Chinese herbal injection

thoracic perfusion combined with cisplatin chemotherapy can improve the ORR of lung cancer

patients with MPE (RR=1.44, 95% CI: $1.35 \sim 1.53$, P = 0.000). In addition, we also performed

subgroup analysis according to different Chinese herbal injection. The results showed that compared

229 with cisplatin thoracic perfusion alone, Aidi injection, Kushen injection and Brucea Javanica oil

emulsion could improve the ORR of lung cancer patients with MPE.

As we all know, lung cancer patients with MPE will have symptoms of chest pain due to poor water circulation. Chemotherapy drugs will inhibit the hematopoietic function of bone marrow, and also affect the digestive function of patients, with vomiting, diarrhea and other digestive tract reactions, further affecting the quality of life of patients. In terms of quality of life, our results showed that Chinese herbal injection could effectively improve the quality of life of patients with lung cancer MPE, and the results of subgroup analysis were consistent with the total results. In addition,Chinese herbal injection thoracic perfusion combined with cisplatin chemotherapy can effectively improve the

238 digestive tract reaction and bone marrow suppression of patients, and the results are statistically 239 significant and consistent with the results of subgroup analysis. Chinese herbal injection thoracic 240 perfusion combined with cisplatin chemotherapy can alleviate chest pain in patients, but the results of 241 subgroup analysis showed no statistical significance, which may be related to the small sample size 242 included in the study. We should consider focusing on this adverse reaction in the future. 243 Although funnel plots for the 29 studys showed that there was significant publication bias in the 244 meta-analysis, there is no significant difference between the results of trim-fill method and the 245 original data, which is favorable to our existing results 246 Our study also have certain limitations, which increase the risk of bias in the outcome indicators of 247 this study. First of all, although this study adopted a relatively extensive search strategy, some 248 conference papers, supplements and grey literature may not be fully obtained, so potential publication 249 bias cannot be excluded. The funnel plot and Begg and Egger test results also reflect some potential 250 publication bias. Among the 29 included studies, only 7 studies described the method of 251 randomization, while the remaining studies did not explain the method of randomization and 252 allocation concealment, and no study mentioned the blinding method, which may lead to potential 253 performance bias and selection bias. Secondly, the sample size of all the included studies was 254 generally small, and the efficacy of the subjects was not tracked. The intervention measures, 255 intervention time and drug administration plan of all the studies were not completely unified, and the 256 forms and effectiveness of the intervention mechanisms could not be clarified. It may increase the 257 imprecision of the outcome indicators and make the evidence strength of the outcome indicators low. 258 Finally, important clinical survival outcomes such as overall survival, progression-free survival, and 259 5-year survival were not fully reported in the included studies. Therefore, high quality and large 260 sample clinical studies are needed in the future to further evaluate the efficacy and safety of Chinese

20

- 261 herbal injection thoracic perfusion combined with cisplatin chemotherapy in the treatment of lung
- 262 cancer MPE, and provide more evidence to support our findings.

263 9 Conclusion

- 264 Our study demonstrated the potencies of Chinese herbal injection thoracic perfusion combined with
- 265 cisplatin chemotherapy to enhance the efficacy and safety for lung cancer MPE patients, improve
- 266 quality of life and decrease adverse reactions. Furthermore, the long-term efficacy of Chinese herbal
- 267 injection in Lung cancer MPE treatment still needs to be verified in future well-designed clinical
- trials that adhere to CONSORT guidelines. More efforts are needed to promote the application of
- 269 Chinese herbal injection in the clinic.

270 Acknowledgments

271 We sincerely thank all support from all authors.

272 Funding Statement

273 This study was supported by National Natural Science Foundation of China (82174465).

274 Data Availability

- 275 The datasets generated during and/or analysed during the current study are available from the
- 276 corresponding author on reasonable request

277 Reference

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics
 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer
 J Clin. 2021;71(3):209-49. Epub 2021/02/05. doi: 10.3322/caac.21660. PubMed PMID: 33538338.

Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer
 patients with pleural effusions. Respirology. 2015;20(4):654-9. Epub 2015/02/24. doi: 10.1111/resp.12496.

283 PubMed PMID: 25706291.

Ryu JS, Ryu HJ, Lee SN, Memon A, Lee SK, Nam HS, et al. Prognostic impact of minimal pleural
 effusion in non-small-cell lung cancer. J Clin Oncol. 2014;32(9):960-7. Epub 2014/02/20. doi:
 10.1200/jco.2013.50.5453. PubMed PMID: 24550423.

Lerza R, Vannozzi MO, Tolino G, Viale M, Bottino GB, Bogliolo G, et al. Carboplatin and cisplatin
 pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol.
 1997;8(4):385-91. Epub 1997/04/01. doi: 10.1023/a:1008203100410. PubMed PMID: 9209670.

Sakaguchi H, Ishida H, Nitanda H, Yamazaki N, Kaneko K, Kobayashi K. Pharmacokinetic evaluation
 of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural
 effusion. Lung Cancer. 2017;104:70-4. Epub 2017/02/19. doi: 10.1016/j.lungcan.2016.12.015. PubMed PMID:
 28213004.

6. Xia Y, Fang P, Zhang X, Su G, Shen A. The efficacy of Endostar combined with platinum pleural infusion for malignant pleural effusion in tumor patients is significantly better than that of monotherapy, but the economy is lower: a systematic review, network meta-analysis and cost-effectiveness analysis. Ann Transl Med. 2022;10(10):604. Epub 2022/06/21. doi: 10.21037/atm-22-2091. PubMed PMID: 35722417; PubMed Central PMCID: PMCPMC9201148.

Zhong LZ, Xu HY, Zhao ZM, Zhang GM, Lin FW. Comparison of efficacy and toxicity between nedaplatin
 and cisplatin in treating malignant pleural effusion. Onco Targets Ther. 2018;11:5509-12. Epub 2018/09/21. doi:
 10.2147/ott.S168391. PubMed PMID: 30233211; PubMed Central PMCID: PMCPMC6134960.

Liu LZ, SS. Li,GM. Effects and safety of compound Kushen injection combined with cisplatin on
 malignant pleural effusion. J Mod Oncol Mod Oncol Hsien Tai Chung Liu Hsueh. 2017;25(02):230-3. doi:
 10.3969/j.issn.1672-4992.2017.02.018.

Shen S. Clinical Effect of Cisplatin Combined with Brucea Javanica Oil Emulsion in Treating Malignant
 Pleural Effussion Caused by Lung Cancer. Chinese Journal of Clinical Rational Drug Use. 2017;10(30). doi: 10.
 15887 /j. cnki. 13-1389 /r. 2017. 30. 005.

308 10. Shi W. Effect of Intrapleural Injection of Addie and Cisplatin in the Treatment of Malignant Pleural
309 Effusion and Malignant Pleural Effusion. China Continuing Medical Education. 2017;9(20):187-9. doi:
310 10.3969/j.issn.1674-9308.2017.20.100.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for
systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. Epub
2015/01/03. doi: 10.1186/2046-4053-4-1. PubMed PMID: 25554246; PubMed Central PMCID:
PMCPMC4320440.

315 12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer.
316 1981;47(1):207-14. Epub 1981/01/01. doi: 10.1002/1097-0142(19810101)47:1<207::aid-
317 cncr2820470134>3.0.co;2-6. PubMed PMID: 7459811.

13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical
test. Bmj. 1997;315(7109):629-34. Epub 1997/10/06. doi: 10.1136/bmj.315.7109.629. PubMed PMID: 9310563;
PubMed Central PMCID: PMCPMC2127453.

22

321 14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj.

322 2003;327(7414):557-60. Epub 2003/09/06. doi: 10.1136/bmj.327.7414.557. PubMed PMID: 12958120; PubMed

323 Central PMCID: PMCPMC192859.

15. Chen FY, HS. Cheng, D. Li, J. Clinical Efficacy and Prognosis of Kingkong Elemene Liposomal Imection
 Combined with Cisplatin for Malignant Pleural Effusion of Lung Cancer. The Practical Journal of Cancer.
 2018;33(07):1169-71. doi: 10.3969/j.issn.1001-5930.2018.07.036.

Han ZT, MQ. Chen,XP. Shi,F. Effect of Closed Drainage Combined with Compound Kushen Injection
 and Cisplatin on Malignant Pleural Effusion of Lung Cancer. Zhejiang Journal of Integrated Traditional Chinese
 and Western Medicine. 2012;22(07):524-6. doi: 10.3969/j.issn.1005-4561.2012.07.011.

He L, Chen Z, Wen S, Ren D, Chen H. Compound Kushen Injection as a Local Therapy for Patients
with Advanced Lung CancerAssociated with Malignant Pleural Effusion. Evaluation and Analysis of Drug-Use in
Hospitals of China. 2010;10(11):1025-7. doi: 10.14009/j.issn.1672-2124.2010.11.012.

Hou T. Clinical Effect Analysis of Aidi Injection and Cisplatin in the Treatment of Lung Cancer
MalignantPleural Effusion. Journal of North Pharmacy. 2017;14(01):178-9. doi: 10.3969/j.issn.16728351.2017.01.152.

Hu JL, QQ. Xie,YS. Intrathoracic administration of Kushenhuangqi Injection combined with cisplatin in
 treatment of malignant pleural effusion. Chinese Journal of General Practitioners. 2008;7(8). doi:
 10.3760/cma.j.issn.1671-7368.2008.08.027.

Li YC, Cp. Li,Qy. Treatment of Lung Cancer Malignant Pleural Effusion with Compound Kushen Injection
 Combined with Cisplatin. China's Naturopathy. 2009;17(04):42. doi: 10.19621/j.cnki.11-3555/r.2009.04.043.

Liu CP, LY. Zhou,B. The Curative Effect of Addie Injection of Traditional Chinese Medicine combined
with Cisplatin on the Treatment of Lung Cancer with Hydrothorax. World Chin Med Shih Chieh Chung I Yao.
2013;8(12):1425-7. doi: 10.3969/j.issn.1673-7202.2013.12.014.

Llu D, Ll D. Curative effect and nursing of thoracic cavity drainage and compound kushen injection
combined with cisplatin in the treatment of lung cancer patients companying with malignant pleural effusion. J
Clin Med Pract Shih Yung Lin Ch'uang I Yao Tsa Chih. 2015;19(08):21-4. doi: 10.7619/jcmp.201508007.

Liu SM, XJ, Shan B, Li Y, Wang S, Chang N, Fu W. Observation of Clinical Efficacy on Malignant Pleural
 Effusion Treated with Cinobufacini Injection and Cisplatin by Intracavitary Perfusion. Chinese Journal of Coal
 Industry Medicine. 2017;20(07):791-4. doi: 10.11723/mtgyyx 1007-9564 201707010.

Meng S. Clinical Study of Aidi Injection Combined with Cisplatin in the Treatment of Lung Cancer
Malignant Pleural Effusion. China Practical Medicine. 2009;4(21):167-8. doi: 10.3969/j.issn.16737555.2009.21.119.

Shi W. Clinical Eficacy and Safety of Compound Matrine Injection Combined with Cisplatin in the
 Treatment of Malignant Pleural Effusion Caused by Lung Cancer. Chinese Journal of Convalescent Medicine.

355 2017;26(08):857-9. doi: 10.13517/j.cnki.ccm.2017.08.032.

Sun SL, M. Clinical Study of Aidi injection Combined with Cisplatin in the Treatment of Lung Cancer
Malignant Pleural Effusion. Mod J Integr Tradit Chin West Med Hsien Tai Chung Hsi I Chieh Ho Tsa Chih.
2012;21(21):2317-8. doi: 10.3969/j.issn.1008-8849.2012.21.018.

27. Tang XJ, MH. Li, JP. Luo, BP. Cinical Objective on Sixty Cases of Compound Kushen Injection Combined

360 withCisplatin in Treatment of Lung Cancer Pleural Effusion. Liaoning Journal of Traditional Chinese Medicine.

361 2018;45(08):1668-70. doi: 10.13192/j.issn.1000-1719.2018.08.036.

Wang H. Intrathoracic administration of Kushenhuangqi Injection combined with cisplatin in treatment
 of malignant pleural effusion. Clinical Research. 2016;24(6).

Wang HL, GQ. Liu,PH. Qu,YM. Xie,GQ. Liu,SX. Brucea Javanica Oil Emulsion Injection Combined with
 Chain in the Treatment of Lung Cancer Malignant Pleural Effusion. Mod Chin Med Chung-kuo Hsien Tai Chung
 Yao, 2007;9(2), Epub 20131012, doi: 10.3969/i.issn.1673-4890.2007.02.009.

367 30. Wang X. Clinical Observation of Aidi Injectio Combined with Cisplatin in the Treatment of Lung Cancer
 368 Malignant Pleural Effusion. China Health Care. 2010;(3). Epub 20101130.

369 31. Wang X. Effect of Aidi Injection Combined with Cisplatin on Intrathoracic Perfusion in Patients with Lung

Cancer Complicated with Malignant Pleural Effusion. Contemporary Medical Symposium. 2014;12(19):255-6.
doi: 10.3969/j.issn.2095-7629.2014.19.221.

Wang Y, Yang H. Effect of Aidi Injection Combined with Cisplatin on Lung Cancer Malignant Pleural
 Effusion. Psychological Doctor. 2017;23(4):136-7.

374 33. Wang YF, SW. Luo,Q. Bai,CF. Li,T. Short-term Effect of Pleural Cavity Drainage and Infusion of
375 Compound Kushen Injection Combined with Cisplatin in the Treatment of Malignant Pleural Effusion of Lung
376 Cancer. World Latest Medicine Information. 2019;19(02):116+21. doi: 10.19613/j.cnki.1671-3141.2019.02.075.

34. Wu CL, J. Wu,XY. Cheng,DW. Clinical study of Compound Radix Sophorae Flavescentis Injection
Combined withCisplatin in Treatment of Malignant Pleural Effusion. Liao-ning Chung I Tsa Chih Liaoning J Tradit
Chin Med. 2019;46(01):85-7. doi: 10.13192/j.issn.1000-1719.2019.01.029.

380 35. Wu MC, YC. Xie, JL. Xie, WM. Effect of intrapleural injection of different drugs in the treatment of pleural
affusion in patients with lung cancer. Chinese Community Doctors. 2020;36(12):83+5. doi: 10.13192/j. issn.
all 1000-1719. 2019. 01. 029.

383 36. Yang D. Efficacy Analysis of Cisplatin Chemotherapy Combined with Aidi Injection in the Treatment of
 384 Lung Cancer Malignant Pleural Effusion. The Medical Forum. 2015;19(28):3937-8.

385 37. Yao Y, Xu H. Treatment of 23 Cases of Malignant Pleural Effusion with Central Venous Catheter
386 Drainage Combined with Aidi Injection and Cisplatin. Che-chiang I Hsueh Zhejiang Med J. 2008;(08):884-6. doi:
387 10.3969/j.issn.1006-2785.2008.08.040.

388 38. Zeng JL, SJ. Effect of Chinese Herbal injection Aidi Injection Combined with Cisplatin on Lung Cancer
 389 MalignantPleural Effusion. Special Health. 2021;(12):61-2.

39. Zhang SC, WL. Meng, SL. Brucea Javanica Oil Emulsion Combined with Chemotherapy Drugs for the
391 Treatment of Malignant Pleural Effusion in Elderly Patients with Lung Cancer. Mod J Integr Tradit Chin West
392 Med Hsien Tai Chung Hsi I Chieh Ho Tsa Chih. 2009;18(15):1749-50. doi: 10.3969/j.issn.1008393 8849.2009.15.026.

394 40. Zhu X. Short-term Efficacy and Nursing Strategies of Pleural Cavity Drainage and Infusion of Compound
 395 Kushen Injection Combined with Cisplatin in the Treatment of Malignant Pleural Effusion of Lung Cancer.
 396 Electronic Journal of Practical Clinical Nursing Science. 2018;3(30):151+3. doi: 10.3969/j.issn.2096-

397 2479.2018.30.123.

Wang,XH. Clinical Observation of Aidi Injectio Combined with Cisplatin in the Treatment of Lung Cancer
 Malignant Pleural Effusion. China Health Care. 2019;18(3):116-117.

400 42. Xu YF, Chen YR, Bu FL, Huang YB, Sun YX, Li CY, et al. Chinese herbal injections versus intrapleural

401 cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of


402 randomized controlled trials. Front Oncol. 2022;12:942941. Epub 2022/10/08. doi: 10.3389/fonc.2022.942941.


- 403 PubMed PMID: 36203451; PubMed Central PMCID: PMCPMC9531116.
- 404
- 405

406			
407			
408			
409			
410			
411			
412			
413			
414			
415			
416			
417			
418			

419			
420			
421			
422			

423





Study ID medRxiv preprint doi: https://doi.org/10.1101/2022.12.01.22283004; this version posted Dece (which was not certified by peer review) is the author/funder, who has granted medRxi	nber 6, 2022. The copyright holder for this preprint	RR (95% CI)	% Weight
medSev preprint do: https://doi.org/10.1101/202.12.01.2228004: this version posted Dece Yao, YW (2008) Meng,SL (2009) Wang,XH (2010) Sun,SL (2012) Liu,CX (2013) Wang,XC (2014) Yang,DF (2015) Wang,Y (2017) Shi,WL (2017) Hou,TJ (2017) Wu,MB (2020) Zeng,J (2021) Liu,C (2013) Wang,XC (2014) Yang,DF (2015) Wang,Y (2017) Shi,WL (2017) Hou,TJ (2017) Wu,MB (2020) Zeng,J (2021) Liu,L (2010) Han,ZQ (2012) Liu,D (2015) Liu,L (2017) Shi,WJ (2017) Zhu,X (2018) Tang,XQ (2018) Wang,Y (2019) Wu,CY (2019) Wang (2007) Zhang,SF (2009) Shen,SL (2017) Wang,HX (2016) Hu,JC (2008) Chen,F (2018) Liu,SY (2017)	r a license to display the preprint in perpetuity.	 2.83 (1.37, 5.88) 1.40 (0.89, 2.22) 1.14 (0.87, 1.49) 1.45 (0.89, 2.36) 1.46 (1.05, 2.04) 1.53 (1.12, 2.08) 1.38 (0.99, 1.91) 1.50 (1.01, 2.24) 1.56 (1.01, 2.40) 1.10 (0.98, 1.23) 1.70 (1.11, 2.61) 1.18 (1.02, 1.37) 1.14 (0.87, 1.49) 1.48 (0.85, 2.60) 1.53 (1.04, 2.25) 1.65 (1.19, 2.30) 1.50 (1.03, 2.19) 1.41 (0.98, 2.02) 1.67 (1.06, 2.62) 1.37 (1.01, 1.86) 1.48 (1.10, 1.99) 1.80 (1.05, 3.08) 1.61 (1.13, 2.30) 1.70 (1.13, 2.58) 1.72 (1.18, 2.52) 1.45 (1.11, 1.91) 1.51 (1.10, 2.07) 1.23 (1.00, 1.53) 1.73 (1.16, 2.60) 	1.11 2.13 4.07 1.94 4.81 3.52 2.96 2.96 1.67 7.41 1.85 6.11 4.07 1.82 2.78 4.07 2.96 3.15 2.22 3.52 4.63 1.85 3.33 2.40 3.33 2.40 3.33 4.07 3.76 8.70 2.78
Overall (I-squared = 38.4%, p = 0.020)	1 5	1.44 (1.35, 1.53) 1 .88	100.00

Study ID

RR (95% CI)

Weight


%

Yao, YW (2008) 3.84 1.55 (0.95, 2.53) Meng,SL (2009) 1.52 (0.86, 2.66) 3.29 Sun,SL (2012) 1.58 (0.86, 2.91) 2.93 10.12 Liu,CX (2013) 1.38 (1.02, 1.87) 6.28 Yang, DF (2015) 1.28 (0.98, 1.67) 1.69 (1.09, 2.63) Han,ZQ (2012) 4.53 Liu,D (2015) 1.62 (1.09, 2.42) 6.56 5.23 Liu,L (2017) 1.53 (1.02, 2.31) 1.50 (1.03, 2.19) Shi,WJ (2017) 5.58 6.28 Tang,XQ (2018) 1.33 (0.95, 1.88) 6.63 Wang,Y (2019) 1.63 (1.10, 2.42) → 1.67 (0.71, 3.89) Wu,CY (2019) 2.09 Wang,HM (2007) 1.60 (1.18, 2.17) 6.98 Zhang,SF (2009) 1.64 (1.13, 2.38) 4.90 Shen,SL (2017) 1.57 (1.13, 2.18) 7.33 Chen, F (2018) 17.44 1.20 (0.99, 1.46) Overall (I-squared = 0.0%, p = 0.943) 1.47 (1.34, 1.61) 100.00 .257 3.89

ID

Yao, YW (2008) Meng,SL (2009) Sun,SL (2012) Liu,CX (2013) Wang,XC (2014) Yang, DF (2015) Hou, TJ (2017) Wang, Y (2017) Wu,MB (2020) Zeng,J (2021) Li,YP (2009) He,L (2010) Han,ZQ (2012) Liu,D (2015) Liu,L (2017) Shi,WJ (2017) Tang,XQ (2018) Wang, Y (2019) Wu,CY (2019) Wang,HM (2007) Zhang,SF (2009) Shen, SL (2017) Hu, JC (2008) Liu,SY (2017) Overall (I-squared = 27.5%, p = 0.106)

.00635



٢

0.36 (0.21, 0.62) 9.61 0.55 (0.15, 2.00) 2.14 0.72 (0.23, 2.31) 2.15 0.64 (0.27, 1.52) 4.50 0.44 (0.21, 0.92) 6.55 0.40 (0.09, 1.87) 2.05 0.67 (0.12, 3.80) 1.23 0.75 (0.29, 1.92) 3.27 0.20 (0.01, 3.89) 1.02 0.14 (0.01, 2.68) 1.43 0.38 (0.11, 1.28) 3.27 0.89 (0.61, 1.30) 6.70 0.86 (0.33, 2.23) 2.86 1.04 (0.41, 2.63) 2.99 0.38 (0.16, 0.94) 5.32 0.36 (0.15, 0.87) 5.73 0.46 (0.20, 1.05) 5.32 1.14 (0.45, 2.89) 2.86 0.04 (0.01, 0.30) 9.41 0.40 (0.08, 1.93) 2.05 0.64 (0.16, 2.56) 1.77 1.11 (0.51, 2.44) 3.68 0.71 (0.53, 0.96) 12.45 1.25 (0.37, 4.23) 1.64 0.56 (0.48, 0.67) 100.00

T. 157

RR (95% CI)

Study ID

Yao, YW (2008)


Meng,SL (2009)

Wang,XH (2010)



0.33 (0.10, 1.08) 3.10 0.41 (0.17, 0.98) 3.97 0.81 (0.61, 1.06) 8.95 0.45 (0.19, 1.09) 3.62

RR (95% CI)





%

Weight

1 Yao, YW (2008) 1 Meng,SL (2009) Sun,SL (2012) Liu,CX (2013) Wang,XC (2014) Hou, TJ (2017) Wang,Y (2017) Wu,MB (2020) Zeng,J (2021) Li,YP (2009) Han,ZQ (2012) Liu,D (2015) Wang,Y (2019) Wang,HM (2007) Zhang,SF (2009) Shen, SL (2017) Hu, JC (2008) Liu,SY (2017) Chen, F (2018) Overall (I-squared = 0.0%, p = 0.631)

.0101

5.00 (0.25, 98.75) 0.59 1.82 (0.18, 18.55) 1.23 1.36 (0.25, 7.27) 2.47 0.44 (0.15, 1.36) 10.59 1.67 (0.43, 6.40) 3.53 1.76 0.33 (0.01, 7.97) 1.33 (0.32, 5.49) 3.53 0.33 (0.04, 2.91) 3.53 5.88 0.20 (0.02, 1.64) 0.38 (0.11, 1.28) 9.41 0.67 (0.12, 3.69) 3.53 1.14 (0.33, 3.97) 4.92 4.71 1.00 (0.27, 3.75) 1.00 (0.07, 15.36) 1.18 1.90 0.29 (0.01, 6.69) 3.00 (0.33, 27.63) 1.18 0.65 (0.12, 3.65) 3.58 0.44 (0.21, 0.92) 18.83 0.33 (0.13, 0.87) 17.65 0.65 (0.47, 0.89) 100.00


98.8


Study ID	RR (95% CI)	% Weight
Aidi injection		
med Row preprint (co. https://oi.org/10.1101/2022.12.01.22283004; this version posted December 6, 2022. The copyright holder for this preprint	2.83 (1.37, 5.88)	1.38
medRxtv preprint to: https://coi.org/10.1101/2022.12.01.22283004; this version posted December 6, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.	1.40 (0.89, 2.22)	2.64
Wang,XH (2010)	1.14 (0.87, 1.49)	5.05
Sun,SL (2012)	1.45 (0.89, 2.36)	2.41
Liu,CX (2013)	1.46 (1.05, 2.04)	5.97
Wang,XC (2014)	1.53 (1.12, 2.08)	4.36
Yang,DF (2015)	1.38 (0.99, 1.91)	3.67
Wang,Y (2017)	1.50 (1.01, 2.24)	3.67
Shi,WL (2017)	1.56 (1.01, 2.40)	2.07
Hou,TJ (2017)	1.10 (0.98, 1.23)	9.18
Wu,MB (2020)	1.70 (1.11, 2.61)	2.29
Zeng,J (2021)	1.18 (1.02, 1.37)	7.57
Subtotal (I-squared = 58.3%, p = 0.006)	1.37 (1.25, 1.50)	50.26
Kushen injection		
Li,YP (2009)	1.14 (0.87, 1.49)	5.05
He,L (2010)	1.48 (0.85, 2.60)	2.25
Han,ZQ (2012)	1.53 (1.04, 2.25)	3.44
Liu,D (2015)	1.65 (1.19, 2.30)	5.04
Liu,L (2017)	1.50 (1.03, 2.19)	3.67
Shi,WJ (2017)	1.41 (0.98, 2.02)	3.90
Zhu,X (2018)	1.67 (1.06, 2.62)	2.75
Tang,XQ (2018)	1.37 (1.01, 1.86)	4.36
Wang,Y (2019)	1.48 (1.10, 1.99)	5.74
- · · · · · · · · · · · · · · · · · · ·		2.29
Wu,CY (2019)	1.80 (1.05, 3.08)	38.50
Subtotal (I-squared = 0.0%, p = 0.813)	1.48 (1.32, 1.66)	30.50
Brucea Javanica oil emulsion		
Wang (2007)	1.61 (1.13, 2.30)	4.13
Zhang,SF (2009)	1.70 (1.13, 2.58)	2.97
Shen,SL (2017)	1.72 (1.18, 2.52)	4.13
Subtotal (I-squared = 0.0%, p = 0.964)	1.68 (1.34, 2.09)	11.24
Overall (I-squared = 45.2%, p = 0.008)	1.45 (1.35, 1.55)	100.00
.17 1	5.88	




Meta-analysis estimates, given named study is omitted

Lower CI Limit Estimate Upper CI Limit










1.47

1.61


1.69

D





в




F

Shen,SL (2017)


Chen,F (2018)


132.34





1.00

A









D

С

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




Figure.1